Dell Stock Set to Benefit From AI and Cloud Applications, Analyst Says. Plus, Twilio, Tradeweb, and More.
Wall Street analysts weigh in on Dell Technologies, Twilio, Tradeweb Markets, Primoris Services, NioCorp Developments, and Compass Therapeutics.
Le Lézard23h
Aileron Therapeutics Announces Rebranding to Rein Therapeutics
Rein Therapeutics ("Rein") , formerly known as Aileron Therapeutics, Inc. ("Aileron") , a biopharmaceutical company advancing a ...
Pharmabiz1d
Quanta receives US FDA clearance to begin phase 1 trial of QTX3544, an oral G12V-preferring, dual ON/OFF state, multi-KRAS inhibitor
Quanta receives US FDA clearance to begin phase 1 trial of QTX3544, an oral G12V-preferring, dual ON/OFF state, multi-KRAS inhibitor: Radnor, Pennsylvania Friday, January 10, 2025 ...
Quanta Announces IND Clearance by U.S. FDA for QTX3544, an Oral G12V-Preferring Multi-KRAS Inhibitor, and Other Pipeline Updates
Additionally, the Phase 1 clinical trial evaluating QTX3034, an oral G12D-preferring multi-KRAS inhibitor, as a monotherapy and in combination with cetuximab, continues to enroll patients, and data is ...
Le Lézard3d
Aspect Biosystems Raises US$115 Million Series B Financing to Advance Bioprinted Tissue Therapeutics
Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics as a new category in regenerative medicine, today announced that it has closed a US$115 million ...
Janux Therapeutics: mCRPC TAM And Promising JANX007's Phase 1 Data
Janux Therapeutics has a robust balance sheet, with $658.1 million in liquid assets and no debt. See why I reiterate my buy ...
Quantum-Si's 327% Rally In Six Months: Is Nvidia The Catalyst For More Gains?
Quantum-Si is a biotech star, with a 327% surge in stock price. Its proteomics platform and partnerships make it one to watch ...
High Q Technologies Announces Commercial Availability and First Sale of the FATHOM™ EPR Spectrometer
High Q Technologies today announced the commercial availability and first sale of FATHOM, a class-leading and innovative EPR ...
Business Wire4d
Acellera Therapeutics Unveils AceForce 1.0: A Novel Family of Next-Generation Neural Network Potential Accelerating Drug Discovery
Acellera Therapeutics, a pioneer in computational chemistry and AI-driven drug discovery, today announced the launch of ...
Pharmaceutical Technology5d
QTX-3046 by Quanta Therapeutics for Lung Cancer: Likelihood of Approval
QTX-3046 is under clinical development by Quanta Therapeutics and currently in Phase I for Lung Cancer. According to GlobalData, Phase I drugs for Lung Cancer have a 78% phase tra ...